[144] Fulgent Genetics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Fulgent Genetics, Inc. (FLGT): An individual identified as Jian Xie proposes to sell 696 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $14,965.08 and an approximate sale date of 08/25/2025 on NASDAQ. The shares were acquired on 02/23/2023 as restricted stock vesting from Fulgent Genetics as equity compensation; the filer shows total acquired amount of 14,573 shares. The issuer has 30,609,044 shares outstanding. The filer reported three prior sales in the past three months totaling 3,008 shares for gross proceeds of $61,471.47. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice; size is immaterial relative to outstanding shares.

The filing documents a proposed sale of 696 shares by Jian Xie, following recent dispositions of 3,008 shares that yielded $61,471.47. The shares to be sold were obtained via restricted stock vesting on 02/23/2023 as equity compensation. Against an issuer base of 30,609,044 shares outstanding, the proposed sale and recent transactions represent a de minimis percentage of the float and are unlikely by themselves to move market valuations. This is a standard Rule 144 disclosure reflecting compliance with resale requirements.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags presented.

The notice provides required detail about acquisition source (restricted stock vesting) and previous transactions within the statutory lookback. The representation that the seller lacks undisclosed material adverse information is included as required. There is no indication in the filing of related-party transactions, unusual payment terms, or a trading plan date; the filing is procedural and consistent with compliance obligations for an insider or person covered by Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	696	14965.08	30609044	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2023	Resticted stock vest	Fulgent Genetics, Inc.			14573	02/23/2023	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	690	14169.92
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	1183	24271.47
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	06/02/2025	1135	23030.08

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the Form 144 for FLGT report?

The notice reports a proposed sale of 696 shares of common stock of Fulgent Genetics (FLGT).

Who is the seller named in the filing?

The filing identifies Jian Xie as the person for whose account the securities are to be sold.

When were the shares to be sold originally acquired?

The shares were acquired on 02/23/2023 through restricted stock vesting as equity compensation from Fulgent Genetics.

What prior sales by the seller are disclosed in the past three months?

Three sales are disclosed: 690 shares and 1,183 shares on 05/27/2025, and 1,135 shares on 06/02/2025, totaling 3,008 shares for gross proceeds of $61,471.47.

Where and when is the proposed sale expected to occur?

The filing lists Morgan Stanley Smith Barney LLC as the broker and an approximate sale date of 08/25/2025 with the market listed as NASDAQ.